Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2022

Aug 3, 2022

30291_dirs_2022-08-03_c6404160-c1f1-4468-97f4-3b5e6a8605f0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2022-08-01

Reporting Person: Murphy Nicole (Head of Pharm Ops and Tech)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-08-01 Common Stock M 255 Acquired 2170.2903 Direct
2022-08-01 Common Stock F 76 $209.26 Disposed 2094.2903 Direct
2022-08-01 Common Stock M 825 Acquired 2919.2903 Direct
2022-08-01 Common Stock F 243 $209.26 Disposed 2676.2903 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-08-01 Restricted Stock Unit $0 J 299 Disposed 2022-08-01 Common Stock (299) Direct
2022-08-01 Restricted Stock Unit $0 M 255 Disposed 2022-08-01 Common Stock (255) Direct
2022-08-01 Restricted Stock Unit $0 M 825 Disposed 2022-08-01 Common Stock (825) Direct

Footnotes

F1: Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan.

F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3: This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting,
which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of
shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of
vested shares = number of shares at target payout times (the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price
following and including the grant date)).

F4: This award was granted to the reporting person on August 1, 2019 and vested in full on August 1, 2022.